Position in ENTA
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$2,374
-$590 QoQ
Shares Held
188
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ENTA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Johnson Financial Group, Inc. holds $3,060,900 across 22 Biotechnology names. ENTA ranks #7 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,418 | $2,640,883 | |
| 2 | EXEL |
Exelixis, Inc.
|
3,858 | $165,469 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
338 | $150,930 | |
| 4 | KLRS |
Kalaris Therapeutics, Inc.
|
10,000 | $57,700 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
687 | $22,822 | |
| 6 | INCY |
Incyte Corp
|
46 | $4,329 | |
| 7 | ENTA |
Enanta Pharmaceuticals Inc
This page
|
188 | $2,374 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
7 | $2,316 |
All Filings in ENTA
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,374 | 188 | Shares | Defined | 2026-05-07 | |
| 2025-12-31 | $2,964 | 188 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $2,250 | 188 | Shares | Defined | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||